Clinical Trial Update: EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating setmelanotide in patients with specific MC4R pathway gene variants for obesity is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genetic Obesity
• Obesity

Drugs mentioned

• Imcivii (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Obesity, Genetic Obesity | Phase 3 | Status: ACTIVE_NOT_RECRUITING